Published On : 15 Jun 2017
QYResearchReports.com has announced the addition of a report titled, “Global Intravenous Immunoglobulin (IVIg) Market Research Report 2017” to its depository. The report conducts an in depth assessment of the leading market drivers, trends, restraints, and developments, alongside market figures and market projections. The major participants in the global market for intravenous immunoglobulin tests have been profiled, wherein their product portfolios, business strategies, and market shares are discussed.
The global market for intravenous immunoglobulin has been advancing steadily, thanks to the explosion of the geriatric population, increasing incidence of bleeding disorders, and growing frequency of chronic inflammatory demyelinating polyneuropathy (CIDP). The aged people are more vulnerable to chronic diseases. As the number of patients suffering from pathological conditions and autoimmune diseases has been escalating by the day, the global demand for intravenous immunoglobulin is expected to multiply. Lupus, celiac disease, and juvenile idiopathic arthritis are some autoimmune conditions that are diagnosed via intravenous immunoglobulin tests.
Increasing number of drug approvals has also been driving the growth of the global intravenous immunoglobulin market. The improvement in the production of IVIg on account of technological advancements is another key catalyst of the market for intravenous immunoglobulin. Emergence of improved purification techniques featuring better plasma yield is also aiding the growth of the market.
Get PDF of Research Summary Of The Repot: https://www.qyresearchreports.com/sample/sample.php?rep_id=1030052&type=E
On the downside, the side effects caused by intravenous immunoglobulin drugs are likely to restrict the growth of the market. The exorbitant costs of IVIg technology might also emerge as another restraint of the market for intravenous immunoglobulin. However, the global intravenous immunoglobulin market will recover from the negative impact of these deterrents as new therapies are being developed.
By type, immunoglobulin M (IgM), immunoglobulin G (IgG), immunoglobulin D (IgD), immunoglobulin A (IgA), and immunoglobulin E (IgE) are the major segments of the market by product type. IgG, IgA, and IgM are often tested together so that doctors can understand key information pertaining to the functioning of the immune system, especially about autoimmune disease or infection. Based on application, the global intravenous immunoglobulin market has been segmented into disease treatment, disease prevention, and disease research.
By region, the global market for intravenous immunoglobulin has been segmented into Europe, Latin America, China, North America, India, Japan, and the Rest of the World (RoW). North America, with the U.S. at the fore, is expected to witness greatest demand for intravenous immunoglobulin over the next few years, emerging as the leading segment of the market. Europe has also been advancing at a considerable pace, with the U.K., France, Germany, and Italy being the leading contributors to the market.
Biotest AG., LFB Group, CSL Limited, Baxter International, Inc., Grifols, S.A., OMRIX Biopharmaceuticals Ltd., Kedrion S.p.A., Octapharma AG, LFB Group, Shanghai RAAS Blood Products Co., Ltd., and Bharat Serums and Vaccines Limited are some key players operating in the global market for intravenous immunoglobulin.
Top Trending Reports :